Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 11/26 11:30:00 am
7785 GBX   -0.19%
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regimen
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue

10/21/2020 | 01:15pm EST

(Adds Federal University of Sao Paulo statement)

SAO PAULO/FRANKFURT, Oct 21 (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.

Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment "there have been no concerns about safety of the clinical trial."

AstraZeneca declined to comment immediately.

A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control group that was given a meningitis jab.

The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, said an independent review committee had also recommended the trial continue. The university earlier confirmed the volunteer was Brazilian but gave no further personal details.

"Everything is proceeding as expected, without any record of serious vaccine-related complications involving any of the participating volunteers," the Brazilian university said in a statement.

So far, 8,000 of the planned 10,000 volunteers in the trial have been recruited and given the first dose in six cities in Brazil, and many have already received the second shot, said a university spokesman.

CNN Brasil reported that the volunteer was a 28-year-old man who lived in Rio de Janeiro and died from COVID-19 complications.

Anvisa provided no further details, citing medical confidentiality of those involved in trials.

AstraZeneca shares fell 1.8%.

Brazil's federal government has plans to purchase the UK vaccine and produce it at biomedical research center FioCruz in Rio de Janeiro, while a competing vaccine from China's Sinovac Biotech Ltd is being tested by Sao Paulo state's research center Butantan Institute.

Brazil's President Jair Bolsonaro said on Wednesday the federal government will not buy the Sinovac vaccine.

Brazil has the second deadliest outbreak of the coronavirus, after the United States, with more than 154,000 killed. It has the third largest number of cases, with more than 5.2 million infected, after the United States and India. (Reporting by Eduardo Simoes in Sao Paulo and Ludwig Burger in Frankfurt; additional reporting by Ricardo Brito and Anthony Boadle in Brasilia and Alistair Smout in London; writing by Jake Spring; editing by Jonathan Oatis and Rosalba O'Brien)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
EURO / BRAZILIAN REAL (EUR/BRL) 0.06% 6.345 Delayed Quote.40.67%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
All news about ASTRAZENECA PLC
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regime..
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
02:11pRussia's Sputnik V developers call on AstraZeneca to try combining vaccines
RE
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
10:58aANALYSIS : Questions over AstraZeneca's COVID-19 vaccine data risk delaying appr..
RE
10:06aWhy the Oxford Astrazeneca Vaccine Is Now a Global Gamechanger
AQ
09:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
09:02a'WE'RE READY' : Schiphol airport gears up for chilled vaccine cargos
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,48 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.85%137 013
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555